CGTX · Cognition Therapeutics Inc
United States · RS rating 10 · As of 2026-10-14
| Price | 0.78 USD |
|---|---|
| 1-day change | -3.1% |
| RS rating (overall / 1M / 3M / 12M) | 10 / 8 / 22 / 12 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 20 / 25 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +58.0% |
| Market cap (USD) | $112.6M |